NewsRoom Articles - Page 2 of 232

ThursdayApr 09, 2026 10:00 am

Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates

The shares of health insurers in the U.S. recorded gains after the Trump administration announced 2027 payment rate increases for Medicare Advantage that were higher than what had been proposed back in January. That improved rate would increase payments to these firms by about $13bn in the coming fiscal year 2027. In January when the federal government revealed that it would be increasing these payments by 0.09%, the insurance firms took a hit to their stock prices because this rate was much lower than had been expected. Investors viewed that small increase as additional pressure on already tight margins, but the surprise announcement of about 2.8% extra payments to MA firms covering older…

WednesdayApr 08, 2026 9:45 am

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually. The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers. The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β. This has now expanded to >20M abstracts representing the totality of scientific literature. Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large…

TuesdayApr 07, 2026 10:00 am

Study Explores Whether a Common Vitamin Could Fight Brain Cancer

Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat. For over two decades, no significant advancement has been made to improve treatment outcomes in patients with glioblastoma. Treatments like radiation, surgery and chemotherapy help, but the tumors regrow and survival times are dismal. The team at the University of Calgary wanted to establish whether vitamin B3 in high doses may boost treatment outcomes when used alongside current treatment approaches. The scientists want to find out whether this…

MondayApr 06, 2026 10:00 am

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

According to a poll conducted by Gallup in March, Americans are most concerned about healthcare. This finding is notable given the escalation in the Iran war and the way events in the Middle East are currently dominating news headlines. Gallup conducted a poll seeking the views of Americans about how much they worry about a list of 15 policy areas on the domestic front. 61% of the respondents revealed that they are greatly worried about healthcare. The next four biggest sources of worry for Americans were connected to economic issues. Those policy issues are the state of the economy, concerns about inflation in the country, spending by…

MondayApr 06, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets South American Mining Sector as Voice-Based Drug and Alcohol Impairment Screening Platform Moves Toward Commercial Deployment

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. The company has appointed Chilean drug policy specialist Felipe Leyton to lead commercialization in South America’s mining industry. The company is preparing to deploy its voice-based AI drug and alcohol impairment detection platform in industrial environments beginning in 2026, with Chile’s mining sector, employing more than 200,000 workers, representing an early target market. MindBio’s technology analyzes voice patterns to detect intoxication or impairment without biological testing, and management is positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries. The…

ThursdayApr 02, 2026 10:00 am

Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031

A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the rapidly growing market for cancer immunotherapy. The report puts the valuation of this market in 2025 at $144.8 billion and projects that it will expand to $311.4 billion by 2031. This expected expansion shows the extent to which patients and clinicians are increasingly accepting immunotherapy as a major approach in cancer care. As a result, these treatments are shifting from being niche therapies and are becoming recognized treatment options by the mainstream medical community and the patients they serve. The…

WednesdayApr 01, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community. Most recently, SNGX announced that a clinical summary of its HyBryte(TM) therapy for cutaneous T-cell lymphoma was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.” The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM)…

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

TuesdayMar 31, 2026 10:00 am

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth. The study, whose findings appeared in the journal Nature, shows that androgens don’t play a part in the development of any other kind of brain tumor. The team’s work shows that when the signaling of these hormones is blocked, the growth of the tumors is blocked. This discovery creates a possibility that treatments could be developed to block these hormones to…

TuesdayMar 31, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. The significance of the UK designation extends beyond a single program. The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease. A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Study Explores Whether a Common Vitamin Could Fight Brain Cancer

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets South American Mining Sector as Voice-Based Drug and Alcohol Impairment Screening Platform Moves Toward Commercial Deployment

Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search